Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment : A single-arm, open-label, phase II study (CheckMate 172)

Schadendorf, Dirk; Ascierto, Paolo A.; Haanen, John; Espinosa, Enrique; Demidov, Lev; Garbe, Claus; Guida, Michele; Lorigan, Paul; Chiarion-Sileni, Vanna; Gogas, Helen; Maio, Michele; Fierro, Maria Teresa; Hoeller, Christoph; Terheyden, Patrick; Gutzmer, Ralf; Guren, Tormod K.; Bafaloukos, Dimitrios; Rutkowski, Piotr; Plummer, Ruth; Waterston, Ashita; Kaatz, Martin; Mandala, Mario; Marquez-Rodas, Ivan; Munoz-Couselo, Eva; Dummer, Reinhard; Grigoryeva, Elena; Young, Tina C.; Nathan, Paul

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment : A single-arm, open-label, phase II study (CheckMate 172)

Autor(en):

Schadendorf, Dirk; Ascierto, Paolo A.; Haanen, John; Espinosa, Enrique; Demidov, Lev; Garbe, Claus; Guida, Michele; Lorigan, Paul; Chiarion-Sileni, Vanna; Gogas, Helen; Maio, Michele; Fierro, Maria Teresa; Hoeller, Christoph; Terheyden, Patrick; Gutzmer, Ralf; Guren, Tormod K.; Bafaloukos, Dimitrios; Rutkowski, Piotr; Plummer, Ruth; Waterston, Ashita; Kaatz, Martin; Mandala, Mario; Marquez-Rodas, Ivan; Munoz-Couselo, Eva; Dummer, Reinhard; Grigoryeva, Elena; Young, Tina C.; Nathan, Paul

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

European Journal of Cancer (2019), Bd. 121, S. 144-153

Verlagsangabe:

Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.ejca.2019.08.014

ISSN:

1879-0852